SC5 - Climate action, environment, resource efficiency and raw materials

About this programme

The Societal Challenge 5 Work Programme focuses on moving to a greener, more resource efficient and climate-resilient economy, with a strong commitment to supporting the UN’s Sustainable Development Goals and the targets of the Paris Agreement.

The work programme for 2018-2020 focuses on several priorities in two general calls with many topics and subtopics:

  • Building a low carbon, climate resilient future: climate action in support of the Paris Agreement
  • Greening the economy in line with the Sustainable Development Goals (SDGs)
    • Circular economy
    • Raw materials
    • Water for our environment, economy and society
    • Innovating cities for sustainability and resilience
    • Protecting and leveraging the value of natural and cultural assets (including earth observation, nature-based solutions, disaster risk reduction, natural capital accounting and heritage alive).
Click to read more 
Hide text 

Your NCP contact for this programme

Image of Kathleen Goris

Kathleen Goris

CURRENTLY ON LEAVE

kathleen.goris@vlaio.be

+32 2 432 42 82

Your PC contact for this programme

Find the contact info on the site of WEWIS

The National Contact Points (NCPs) provide support, guidance, and practical information to potential applicants, helping them navigate funding opportunities and application processes.

The Programme Committee (PC) members represent their country in decision-making about the work programmes, evaluate implementation, and provide strategic input on priorities and calls.

Latest news

Upcoming events

No events that are specifically related to SC5 - Climate action, environment, resource efficiency and raw materials were found. Check the full calendar.

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.